Massachusetts Panel Urges Action on Xylazine and Emerging Drug Threats

A Massachusetts state commission has issued a comprehensive set of recommendations for addressing the evolving threat of xylazine and other emerging contaminants in the illicit drug supply, calling for expanded low-barrier treatment, improved drug monitoring systems, and coordinated statewide education efforts.

The Special Commission on the Public Health Effects of Xylazine, co-chaired by Senator John C. Velis and Representative Mindy Domb, submitted its final report after months of investigation into what the commission describes as a "rapidly evolving street-drug supply." The findings reveal a shifting landscape where one dangerous adulterant gives way to another even as policymakers struggle to respond.

The Shifting Contamination Picture

Xylazine, a veterinary sedative not approved for human use by the FDA, first appeared in Massachusetts drug samples in measurable quantities in 2022. According to data from the Massachusetts Drug Supply Data Stream (MAADS), xylazine was present in 5% of opioid-overdose-related deaths that year, with 19% of collected samples testing positive.

By 2024, that figure had climbed to 26%. Yet the commission's report documents a more recent decline—to 13% by June 2025—accompanied by what researchers call "the almost simultaneous rise in the presence of other sedatives like medetomidine."

Medetomidine, another veterinary drug sometimes referred to as "rhino tranq" due to its use in large animal sedation, produces similar public health challenges. Both compounds complicate overdose response because they are not opioids and do not respond to naloxone, the standard overdose reversal medication. When combined with fentanyl—which remains the primary driver of overdose deaths—the sedatives create a dangerous synergy that can suppress breathing and cause prolonged unconsciousness.

The commission found that xylazine entering Massachusetts comes primarily from international online vendors rather than diversion from legitimate veterinary sources. The substance costs less than $10 per kilogram and mimics the sedative effects of opioids, making it an attractive adulterant for illicit drug suppliers.

Health Harms Beyond Overdose

The commission's report details health consequences that extend far beyond acute overdose. Xylazine exposure causes severe skin ulcers that can appear at injection sites or elsewhere on the body—wounds that may take months or years to heal and often require extensive medical care.

"Xylazine causes extreme sedation that can impact a person's ability to breathe" immediately upon exposure, the report notes. Days later, individuals may develop severe wounds "beyond the site of injection that can take weeks or even months to heal and often do not heal without consistent wound care."

Long-term effects include physical dependence on xylazine itself, which produces withdrawal symptoms distinct from opioid withdrawal. This dual dependence complicates treatment, as individuals may experience withdrawal from both the opioid and the sedative components of their drug use.

The report also warns about additional contaminants appearing in drug samples, including nitazenes—a class of synthetic opioids that can be more potent than fentanyl and may require multiple doses of naloxone to reverse.

Recommendations for a Public Health Response

The commission organized its recommendations into three areas: oversight and enforcement, outreach and treatment, and education and training.

Notably, the commission recommended against rescheduling xylazine under state law, warning that additional restrictions could limit legitimate veterinary access without addressing the illicit supply. Instead, the report advocates for "public health policies that reduce the harms associated with xylazine exposure rather than implementing additional penalties or restrictions."

For outreach and treatment, the commission emphasizes the effectiveness of low-barrier care and mobile intervention programs. The report recommends expanding these services "particularly in rural areas where transportation remains a barrier," including mobile care services, street outreach campaigns, and walk-in treatment sites with extended hours.

Senator Velis, currently on active-duty deployment with the Massachusetts National Guard, issued a statement emphasizing the broader applicability of the commission's approach. "Most importantly, the report provides a comprehensive example for how the Commonwealth can respond swiftly to other harmful emerging contaminants in the drug supply to ultimately save lives."

The Challenge of Education

The commission identified significant gaps in awareness among both healthcare providers and people who use drugs. Clinician awareness of xylazine risks "varies widely across the state," the report found, recommending standardized training developed by public health agencies in collaboration with medical experts.

For people who use drugs, the commission found that delayed care-seeking often results from lack of awareness about how wounds develop or their connection to xylazine exposure. The report recommends educational materials addressing what xylazine is, signs of exposure, wound care, and harm reduction measures—including how to access and use drug-checking tools.

The commission also emphasized the need for "universal access to consistent, accurate, and current information on contaminants and other changes in the drug supply," recognizing that the specific substances of concern will continue to evolve.

National Implications

Massachusetts is not unique in confronting xylazine and related contaminants. The CDC issued a Health Alert Network advisory about medetomidine in early April, warning that the compound—like xylazine—does not respond to naloxone and can cause severe withdrawal symptoms. The Drug Enforcement Administration has documented xylazine's presence in drug samples across multiple regions.

The Massachusetts commission's approach—focusing on harm reduction, treatment access, and real-time monitoring rather than criminalization—reflects a growing consensus among public health researchers about how to address an adulterant supply that shifts faster than regulatory frameworks can adapt.

For people seeking opioid addiction treatment, the report underscores the importance of low-barrier access to care that can address the complex medical needs created by modern drug contamination. As the commission's findings demonstrate, effective response requires not just overdose reversal medications but comprehensive wound care, withdrawal management, and ongoing support services.

The commission's work offers a template that other states might adapt as they confront similar challenges in their own drug supplies—recognizing that today's xylazine crisis may give way to tomorrow's medetomidine challenge, and that sustainable response requires flexible, public-health-oriented infrastructure rather than substance-specific interventions.